Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam

Carcinogenesis. 1993 Jul;14(7):1487-9. doi: 10.1093/carcin/14.7.1487.


Piroxicam inhibited induction of transitional cell carcinoma in mouse urinary bladder by N-butyl-N-(4-hydroxybutyl)-nitrosamine. At 15 mg piroxicam/kg diet, tumor incidence was reduced 82% (P < 0.0001) compared with carcinogen controls. At 30 mg piroxicam/kg diet, tumor incidence was reduced 70% (P < 0.001). Results at the higher dose level suggested that piroxicam also may have inhibited invasion slightly. Combination treatment with 2-difluoromethyl-ornithine (DFMO) or all-trans-N-(4-hydroxyphenyl)retinamide (4-HPR) or both agents did not improve the chemopreventive potential of piroxicam. However, the three-agent combination of 30 mg piroxicam/kg, 1200 mg DFMO/kg and 313 mg 4-HPR/kg diet was highly effective. Tumor incidence was reduced 91% (P < 0.0001) compared with carcinogen controls. Unfortunately, the high efficacy was somewhat compromised by a significant decrease in survival and body weight gain in mice receiving the combination of agents compared with the carcinogen control.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Butylhydroxybutylnitrosamine*
  • Carcinoma, Transitional Cell / chemically induced
  • Carcinoma, Transitional Cell / prevention & control*
  • Drug Synergism
  • Eflornithine / pharmacology
  • Fenretinide / therapeutic use
  • Male
  • Mice
  • Piroxicam / pharmacology*
  • Urinary Bladder Neoplasms / chemically induced
  • Urinary Bladder Neoplasms / prevention & control*


  • Piroxicam
  • Fenretinide
  • Butylhydroxybutylnitrosamine
  • Eflornithine